1. Altered Expression of RB and pRB in Tissue Arrays of Primary Breast Cancers and Matched Axillary Lymph Node Metastases.
- Author
-
Leser, Carmen, Reiner, Angelika, Dorffner, Georg, Kastner, Marie-Theres, Igaz, Martin, Singer, Christian, König-Castillo, Deirdre Maria, Deutschmann, Christine, König, Daniel, Holzer, Iris, and Gschwantler-Kaulich, Daphne
- Subjects
- *
PROTEINS , *TISSUE arrays , *DISEASE progression , *STAINS & staining (Microscopy) , *AXILLA , *IMMUNOHISTOCHEMISTRY , *METASTASIS , *LYMPH nodes , *GENE expression , *TRANSFERASES , *RETINOBLASTOMA , *BREAST tumors , *CYTOPLASM - Abstract
Objectives. The retinoblastoma (RB) pathway is crucial in the development and progression of many cancers. To better understand the biology of progressive breast cancer (BC), we examined protein expression of the RB pathway in primary BCs and matched axillary lymph node metastases (LM). Methods. Immunohistochemistry was used to evaluate cyclin D1, CDK4/6, RB, phosphorylated RB (pRB), and E2F1 expression in tissue arrays containing cores of 50 primary BCs and matched LM. The number of positive tumor cells and staining intensity were scored. Results. The proteins were localized in the nucleus, while CDK6 was detected in the cytoplasm and CDK4 was found in both. pRB and E2F1 showed higher expression in matched LM than in primary tumors. Expression of these proteins differed significantly by the percentage of positive tumor cells, while proteins in the proximal portion of the RB pathway showed no significant differences. The main path of alteration consisted of high pRB in primary BC, remaining pRB high in the majority of LM, variations occurring in fewer cases. All matched LM of the few primary tumors that had unaltered RB and pRB expression showed changes in RB or pRB expression. Conclusion. Expression of pRB and E2F1 was significantly higher in LM than in primary BC. A majority of cancers with LM showed altered RB or pRB expression, suggesting that proteins downstream in the RB pathway play a critical role in metastatic BC and disease progression. So looking at the RB pathway could be an option for chemotherapy decisions in patients with only few LM. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF